QTX3034 + Cetuximab for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a new drug, QTX3034, is safe and tolerable for individuals with certain advanced solid tumors. It targets cancers with a specific change in the KRAS gene, commonly found in many solid tumors. The trial will test QTX3034 both alone and in combination with another cancer drug, cetuximab. Individuals with these tumors who have tried at least one other cancer treatment may be suitable candidates. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that QTX3034, whether used alone or with cetuximab, is generally safe. In studies, patients tolerated it well, and clear evidence indicates that the treatment works as expected. These findings suggest that the treatment is usually well-tolerated, with no major safety issues reported. This information comes from early trials focusing on safety and how the treatment works in the body. Prospective participants in a clinical trial for QTX3034 may find these results encouraging. However, it is important to consult a healthcare provider to understand what this could mean personally.12345
Why are researchers excited about this trial's treatments?
QTX3034 is unique because it targets solid tumors with a novel mechanism, potentially offering a new angle of attack compared to existing chemotherapy and targeted therapies like cetuximab alone. Most treatments for solid tumors work by either directly killing cancer cells or blocking growth signals. However, QTX3034, when combined with cetuximab, might enhance the efficacy of cetuximab by specifically targeting additional pathways involved in tumor growth and resistance. Researchers are excited because this combination could lead to more effective treatments with potentially fewer side effects, offering new hope for patients with hard-to-treat solid tumors.
What evidence suggests that this trial's treatments could be effective for solid tumors?
Research has shown that QTX3034, when combined with cetuximab, has promising effects against certain cancers. One study found that three out of twelve patients experienced tumor shrinkage, particularly those with pancreatic ductal cancer. The combination also proved effective against tumors in patients with colorectal cancer. In this trial, participants will receive either QTX3034 alone or in combination with cetuximab. Although these results are preliminary, they suggest that QTX3034, especially with cetuximab, might help treat these challenging cancers.12367
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors that have a specific KRAS G12D mutation, confirmed by certified testing. Participants must have tried at least one systemic therapy before and should be in good physical condition (ECOG status 0 or 1). They need to have measurable disease as defined by RECIST criteria and their organs must function well.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive QTX3034 as monotherapy or in combination with cetuximab in dose-escalation and dose-expansion phases
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of treatment-emergent adverse events and duration of response
What Are the Treatments Tested in This Trial?
Interventions
- QTX3034
Find a Clinic Near You
Who Is Running the Clinical Trial?
Quanta Therapeutics
Lead Sponsor